In bladder cancer, WTAP/YTHDF1 promotes cell viability of bladder cancer and inhibits erastin-induced ferroptosis by promoting the levels of the antioxidant factor NRF2 mRNA. This evidence concerns the gene NFE2L2 and urinary bladder cancer.